Skip to main content

PAPEL DE LOS RECEPTORES NUCLEARES VDR Y AHR EN LA RESPUESTA ANTI-INFLAMATORIA Y PRO-RESOLUTIVA FRENTE A LA INSUFICIENCIA CARDIACA

PID2020-113238RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NOD1 in the interplay between microbiota and gastrointestinal immune adaptations

  • Fernández-García, Victoria
  • González-Ramos, Silvia
  • Martín-Sanz, Paloma
  • García del Portillo, Francisco
  • Moisés Laparra, José
  • Boscá, Lisardo
© 2021 The Author(s)., Nucleotide-binding oligomerization domain 1 (NOD1), a pattern recognition receptor (PRR) that detects bacterial peptidoglycan fragments and other danger signals, has been linked to inflammatory pathologies. NOD1, which is expressed by immune and non-immune cells, is activated after recognizing microbe-associated molecular patterns (MAMPs). This recognition triggers host defense responses and both immune memory and tolerance can also be achieved during these processes. Since the gut microbiota is currently considered a master regulator of human physiology central in health and disease and the intestine metabolizes a wide range of nutrients, drugs and hormones, it is a fact that dysbiosis can alter tissues and organs homeostasis. These systemic alterations occur in response to gastrointestinal immune adaptations that are not yet fully understood. Even if previous evidence confirms the connection between the microbiota, the immune system and metabolic disorders, much remains to be discovered about the contribution of NOD1 to low-grade inflammatory pathologies such as obesity, diabetes and cardiovascular diseases. This review compiles the most recent findings in this area, while providing a dynamic and practical framework with future approaches for research and clinical applications on targeting NOD1. This knowledge can help to rate the consequences of the disease and to stratify the patients for therapeutic interventions., The review was written by authors that work in a laboratory where projects are supported by: Ministerio de Economía, Industria y Competitividad/Agencia Estatal de Investigación 10.13039/501100011033 (RTI2018-094727-B100, SAF2017-82436-R, BIO2016-77639-P, PID2019-108977-RBI00 and PID2020-113238-RBI00), Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222), Consorcio de Investigación en Red de la Comunidad de Madrid, S2017/BMD-3686 and Fondo Europeo de Desarrollo Regional.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Unraveling the interplay between iron homeostasis, ferroptosis and extramedullary hematopoiesis

  • Fernández-García, Victoria
  • González-Ramos, Silvia
  • Martín-Sanz, Paloma
  • Castrillo, Antonio
  • Boscá, Lisardo
Iron participates in myriad processes necessary to sustain life. During the past decades, great efforts have been made to understand iron regulation and function in health and disease. Indeed, iron is associated with both physiological (e.g., immune cell biology and function and hematopoiesis) and pathological (e.g., inflammatory and infectious diseases, ferroptosis and ferritinophagy) processes, yet few studies have addressed the potential functional link between iron, the aforementioned processes and extramedullary hematopoiesis, despite the obvious benefits that this could bring to clinical practice. Further investigation in this direction will shape the future development of individualized treatments for iron-linked diseases and chronic inflammatory disorders, including extramedullary hematopoiesis, metabolic syndrome, cardiovascular diseases and cancer., Work in the authors laboratory is supported by: Ministerio de Economía, Industria y Competitividad/Agencia Estatal de Investigación 10.13039/501100011033 (PID2019-108977RB-I00 and PID2020-113238RB-I00), Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222), Consorcio de Investigación en Red de la Comunidad de Madrid, S2017/BMD-3686 and Fondo Europeo de Desarrollo Regional.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Defining the metabolic signatures associated with human macrophage polarisation

  • Povo-Retana, Adrián
  • Landauro-Vera, Rodrigo
  • Fariñas, Marco
  • Sánchez-García, Sergio
  • Álvarez-Lucena, Carlota
  • Marín, Silvia
  • Cascante, Marta
  • Boscá, Lisardo
Macrophages are essential components of the innate immune system that play both homeostatic roles in healthy organs, and host defence functions against pathogens after tissue injury. To accomplish their physiological role, macrophages display different profiles of gene expression, immune function, and metabolic phenotypes that allow these cells to participate in different steps of the inflammatory reaction, from the initiation to the resolution phase. In addition, significant differences exist in the phenotype of macrophages depending on the tissue in which they are present and on the mammalian species. From a metabolic point of view, macrophages are essentially glycolytic cells; however, their metabolic fluxes are dependent on the functional polarisation of these cells. This metabolic and cellular plasticity offers the possibility to interfere with the activity of macrophages to avoid harmful effects due to persistent activation or the release of molecules that delay tissue recovery after injury., This work has been supported by Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación 10.13039/501100011033 (PID2020-113238RB-I00, PID2020-115051RB-I00 and CPP2021-008392, co-financed by NextGenerationEU’/PRTR), and Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CB16/11/00222) y Enfermedades Hepáticas y Digestivas (CB17/04/00023) from the Instituto de Salud Carlos III (co-financed by the European Development Regional Fund ‘A Way to Achieve Europe’); Comunidad de Madrid Programa Biociencias (P2022-BMD-7223); from AGAUR (2021 SGR 00350) and ICREA foundation (ICREA-Academia-2021 to M.C.) of Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lipoxin-mediated signaling: ALX/FPR2 interaction and beyond

  • Sánchez-García, Sergio
  • Jaén, Rafael I.
  • Fernández-Velasco, María
  • Delgado, Carmen
  • Boscá, Lisardo
  • Prieto, Patricia
In the aftermath of tissue injury or infection, an efficient resolution mechanism is crucial to allow tissue healing and preserve appropriate organ functioning. Pro-resolving bioactive lipids prevent uncontrolled inflammation and its consequences. Among these mediators, lipoxins were the first described and their pro-resolving actions have been mainly described in immune cells. They exert their actions mostly through formyl-peptide receptor 2 (ALX/FPR2 receptor), a G-protein-coupled receptor whose biological function is tremendously complex, primarily due to its capacity to mediate variable cellular responses. Moreover, lipoxins can also interact with alternative receptors like the cytoplasmic aryl hydrocarbon receptor, the cysteinyl-leukotrienes receptors or GPR32, triggering different intracellular signaling pathways. The available information about this complex response mediated by lipoxins is addressed in this review, going over the different mechanisms used by these molecules to stop the inflammatory reaction and avoid the development of dysregulated and chronic pathologies., This work has been supported by: Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación 10.13039/501100011033 (PID2020–113238RB-I00; ERDF A way of making Europe), and Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222) from the Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”) and Comunidad de Madrid Programa Biociencias (S2022-BMD-7223)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Contribution of Nucleotide-Binding Oligomerization Domain-like (NOD) Receptors to the Immune and Metabolic Health

  • Jeri Apaza, César
  • Días, Marisol
  • García Tejedor, Aurora
  • Boscá, Lisardo
  • Laparra, José Moisés
Nucleotide-binding oligomerization domain-like (NOD) receptors rely on the interface between immunity and metabolism. Dietary factors constitute critical players in the activation of innate immunity and modulation of the gut microbiota. The latter have been involved in worsening or improving the control and promotion of diseases such as obesity, type 2 diabetes, metabolic syndrome, diseases known as non-communicable metabolic diseases (NCDs), and the risk of developing cancer. Intracellular NODs play key coordinated actions with innate immune ‘Toll-like’ receptors leading to a diverse array of gene expressions that initiate inflammatory and immune responses. There has been an improvement in the understanding of the molecular and genetic implications of these receptors in, among others, such aspects as resting energy expenditure, insulin resistance, and cell proliferation. Genetic factors and polymorphisms of the receptors are determinants of the risk and severity of NCDs and cancer, and it is conceivable that dietary factors may have significant differential consequences depending on them. Host factors are difficult to influence, while environmental factors are predominant and approachable with a preventive and/or therapeutic intention in obesity, T2D, and cancer. However, beyond the recognition of the activation of NODs by peptidoglycan as its prototypical agonist, the underlying molecular response(s) and its consequences on these diseases remain ill-defined. Metabolic (re)programming is a hallmark of NCDs and cancer in which nutritional strategies might play a key role in preventing the unprecedented expansion of these diseases. A better understanding of the participation and effects of immunonutritional dietary ingredients can boost integrative knowledge fostering interdisciplinary science between nutritional precision and personalized medicine against cancer. This review summarizes the current evidence concerning the relationship(s) and consequences of NODs on immune and metabolic health., This work was financially supported by grants Food4ImNut (PID2019-107650RB-C22), PID2020-113238RB-I00 from MICIU/AEI 13039/501100011033, and Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222) from the Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”, by the “European Union” and by the “European Union NextGeneration EU/PRTR”); Comunidad de Madrid Programa Biociencias (S2022-BMD-7223)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Crosstalk between P2Y receptors and cyclooxygenase activity in inflammation and tissue repair

  • Povo-Retana, Adrián
  • Sánchez-García, Sergio
  • Álvarez-Lucena, Carlota
  • Landauro-Vera, Rodrigo
  • Prieto, Patricia
  • Delgado, Carmen
  • Martín-Sanz, Paloma
  • Boscá, Lisardo
The role of extracellular nucleotides as modulators of inflammation and cell stress is well established. One of the main actions of these molecules is mediated by the activation of purinergic receptors (P2) of the plasma membrane. P2 receptors can be classified according to two different structural families: P2X ionotropic ion channel receptors, and P2Y metabotropic G protein-coupled receptors. During inflammation, damaged cells release nucleotides and purinergic signaling occurs along the temporal pattern of the synthesis of pro-inflammatory and pro-resolving mediators by myeloid and lymphoid cells. In macrophages under pro-inflammatory conditions, the expression and activity of cyclooxygenase 2 significantly increases and enhances the circulating levels of prostaglandin E2 (PGE2), which exerts its effects both through specific plasma membrane receptors (EP1-EP4) and by activation of intracellular targets. Here we review the mechanisms involved in the crosstalk between PGE2 and P2Y receptors on macrophages, which is dependent on several isoforms of protein kinase C and protein kinase D1. Due to this crosstalk, a P2Y-dependent increase in calcium is blunted by PGE2 whereas, under these conditions, macrophages exhibit reduced migratory capacity along with enhanced phagocytosis, which contributes to the modulation of the inflammatory response and tissue repair., This work has been supported by: Ministerio de Ciencia, Investigación y Universidades, Agencia Estatal de Investigación https://doi.org/10.13039/501100011033 (PID2020-113238RB-I00 and PID2019-108977RB-I00), Comunidad de Madrid Programa Biociencias (P2022-BMD-7223), and Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222) from the Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment—Progresses in Their Use in Combined Cancer Therapy

  • Povo-Retana, Adrián
  • Landauro-Vera, Rodrigo
  • Álvarez-Lucena, Carlota
  • Cascante, Marta
  • Boscá, Lisardo
Trabectedin (TRB) and Lurbinectedin (LUR) are alkaloid compounds originally isolated from Ecteinascidia turbinata with proven antitumoral activity. Both molecules are structural analogues that differ on the tetrahydroisoquinoline moiety of the C subunit in TRB, which is replaced by a tetrahydro-β-carboline in LUR. TRB is indicated for patients with relapsed ovarian cancer in combination with pegylated liposomal doxorubicin, as well as for advanced soft tissue sarcoma in adults in monotherapy. LUR was approved by the FDA in 2020 to treat metastatic small cell lung cancer. Herein, we systematically summarise the origin and structure of TRB and LUR, as well as the molecular mechanisms that they trigger to induce cell death in tumoral cells and supporting stroma cells of the tumoral microenvironment, and how these compounds regulate immune cell function and fate. Finally, the novel therapeutic venues that are currently under exploration, in combination with a plethora of different immunotherapeutic strategies or specific molecular-targeted inhibitors, are reviewed, with particular emphasis on the usage of immune checkpoint inhibitors, or other bioactive molecules that have shown synergistic effects in terms of tumour regression and ablation. These approaches intend to tackle the complexity of managing cancer patients in the context of precision medicine and the application of tailor-made strategies aiming at the reduction of undesired side effects., This work has been supported by: PID2020-113238RB-I00 from MICIN/AEI 13039/501100011033, and Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CB16/11/00222) and Enfermedades Hepáticas y Digestivas (CB17/04/00023) from the Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”, by the “European Union” and by the “European Union NextGeneration EU/PRTR”); Comunidad de Madrid Programa Biociencias (S2022-BMD-7223)., Peer reviewed